| The molecular mechanism of nuclear transport revealed by atomic-scale measurements LE Hough, K Dutta, S Sparks, DB Temel, A Kamal, J Tetenbaum-Novatt, ... Elife 4, e10027, 2015 | 155 | 2015 |
| Orthogonal methods for characterizing the unfolding of therapeutic monoclonal antibodies: differential scanning calorimetry, isothermal chemical denaturation, and intrinsic … DB Temel, P Landsman, ML Brader Methods in enzymology 567, 359-389, 2016 | 85 | 2016 |
| Regulatory interactions between a bacterial tyrosine kinase and its cognate phosphatase DB Temel, K Dutta, S Alphonse, J Nourikyan, C Grangeasse, R Ghose Journal of Biological Chemistry 288 (21), 15212-15228, 2013 | 34 | 2013 |
| Deciphering the “fuzzy” interaction of FG nucleoporins and transport factors using small-angle neutron scattering S Sparks, DB Temel, MP Rout, D Cowburn Structure 26 (3), 477-484. e4, 2018 | 20 | 2018 |
| Utility of solution x-ray scattering for the development of antibody biopharmaceuticals H Inouye, D Houde, DB Temel, L Makowski Journal of Pharmaceutical Sciences 105 (11), 3278-3289, 2016 | 18 | 2016 |
| Evaluation of incremental siliconization levels on soluble aggregates, submicron and subvisible particles in a prefilled syringe product S Bai, P Landsman, A Spencer, D DeCollibus, F Vega, DB Temel, ... Journal of Pharmaceutical Sciences 105 (1), 50-63, 2016 | 17 | 2016 |
| Solution structure and DNA-binding properties of the phosphoesterase domain of DNA ligase D A Natarajan, K Dutta, DB Temel, PA Nair, S Shuman, R Ghose Nucleic acids research 40 (5), 2076-2088, 2012 | 8 | 2012 |
| Developability in biophysical characterization DB Temel, F Kinderman, E Eryilmaz Biophysical characterization of proteins in developing biopharmaceuticals …, 2020 | 7 | 2020 |
| Sequence-specific backbone 1H, 13C and 15N assignments of the catalytic domain of the Escherichia coli protein tyrosine kinase, Wzc DB Temel, K Dutta, R Ghose Biomolecular NMR assignments 8, 37-41, 2014 | 3 | 2014 |
| Resolving liquid-liquid phase separation for a peptide fused monoclonal antibody by formulation optimization W Qi, L Alekseychyk, N Nuanmanee, DB Temel, V Jann, M Treuheit, ... Journal of Pharmaceutical Sciences 110 (2), 738-745, 2021 | 2 | 2021 |
| Atomic Scale Dynamic Behavior of the Nuclear Transport Selectivity Barrier L Hough, K Dutta, A Kamal, D Temel, S Sparks, J Tetenbaum-Novatt, ... Molecular biology of the cell 25, 2014 | 1 | 2014 |
| Engineering monoclonal antibodies to improve stability and production titer JL Stevens, D Temel, B Estes, NJ Agrawal US Patent App. 17/420,231, 2022 | | 2022 |
| Deciphering the'fuzzy'interaction of FG nucleoporins and transport factors using SANS D Cowburn, S Sparks, DB Temel, MP Rout Acta Crystallographica Section A: Foundations and Advances 75, a395-a395, 2019 | | 2019 |
| The Role of Intrinsic Disorder in the Molecular Mechanism of Nuclear Transport LK Maguire, K Wall, G Armstrong, K Dutta, S Sparks, DB Temel, A Kamal, ... Biophysical Journal 110 (3), 558a, 2016 | | 2016 |
| The Behavior of the Intrinsically Disordered FG Nups Determined by in Cell NMR L Hough, K Dutta, A Kamal, D Temel, S Sparks, J Tetenbaum-Novatt, ... Biophysical Journal 104 (2), 120a, 2013 | | 2013 |
| Interactions between a Bacterial Tyrosine Kinase and its Cognate Phosphatase--- A Solution NMR Study DB Temel Dissertation Abstracts International 73 (108), 2012, 2012 | | 2012 |
| Utility of X-ray scattering for the development of antibody biopharmaceuticals H Inouye, D Houde, DB Temel, L Makowski | | |
